Clinical Trial Update: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia [Phase 1]

View source ↗

Summary

Phase 1 study of KRN23 in X-linked hypophosphatemia with osteomalacia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomalacia
• X-linked Hypophosphatemia

Drugs mentioned

• KRN23 (burosumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: X-linked Hypophosphatemic Rickets/Osteomalacia | Phase 1 | Status: COMPLETED